Targeted treatment approaches and pathogenicity of antibody subclasses in MuSK-myasthenia gravis
<p>Muscle Specific Kinase myasthenia gravis (MuSK-MG) is an autoimmune disease that impairs neuromuscular transmission leading to muscle fatigability. No targeted medications are currently available, and non-specific immunotherapies are required. MuSK initiates a phosphorylation cascade regula...
1. Verfasser: | Cao, M |
---|---|
Weitere Verfasser: | Beeson, D |
Format: | Abschlussarbeit |
Sprache: | English |
Veröffentlicht: |
2021
|
Schlagworte: |
Ähnliche Einträge
Ähnliche Einträge
-
Infantile Onset Myasthenia Gravis with MuSK Antibodies
von: J Gordon Millichap
Veröffentlicht: (2006-08-01) -
MuSK Antibody Positive Myasthenia Gravis Mimicking as Myositis
von: Nilesh Wagh, et al.
Veröffentlicht: (2024-09-01) -
Clinical Characteristics of MuSK Antibody-positive Myasthenia Gravis in Taiwan
von: Yung-Chuan Huang, et al.
Veröffentlicht: (2008-07-01) -
Myasthenia Crisis as First Presentation of MuSk Positive Myasthenia Gravis: A Case Report
von: Dipesh Chhetri, et al.
Veröffentlicht: (2025-02-01) -
Coexistence of anti-MuSK antibody-positive myasthenia gravis and rheumatoid arthritis
von: Amber Eker, et al.
Veröffentlicht: (2020-08-01)